Hebei Medical University Fourth Hospital
160
49
54
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
3.1%
5 terminated/withdrawn out of 160 trials
76.2%
-10.3% vs industry average
13%
21 trials in Phase 3/4
6%
1 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (160)
Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
Role: lead
A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction
Role: lead
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
Role: collaborator
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors
Role: collaborator
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer
Role: lead
Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation
Role: collaborator
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Role: collaborator
A Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant Therapy
Role: lead
Sedation in ICU Patients With Mechanical Ventilation
Role: collaborator
Laparoscopic Staging for Stage III Gastric Cancer
Role: collaborator
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Role: lead
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Role: lead
Modified Tumor-free Techniques Operation to Cervical Cancer
Role: collaborator
Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors
Role: lead
Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics
Role: lead
Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
Role: collaborator
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
Role: lead
Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection
Role: lead
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
Role: lead
CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer
Role: collaborator